Search Results

You are looking at 31 - 40 of 886 items for :

  • "risk factor" x
  • Refine by Access: All x
Clear All
Full access

NCCN Guidelines as a Model of Extended Criteria for Lung Cancer Screening

Brady J. McKee, Shawn Regis, Andrea K. Borondy-Kitts, Jeffrey A. Hashim, Robert J. French Jr, Christoph Wald, and Andrea B. McKee

(NLST) entry criteria. 1 – 4 All 3 organizations have expanded their screening recommendations to include older patients, younger patients, and/or patients with additional risk factors for lung cancer. Inclusion of these additional populations has

Full access

Perioperative Intravesical Chemotherapy in Non–Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis

Michael R. Abern, Richmond A. Owusu, Mark R. Anderson, Edward N. Rampersaud, and Brant A. Inman

recurrence rates. In addition, the authors seek to analyze whether this effect varies by drug or by baseline patient risk factors. Methods Literature Search Strategy The authors searched the Cochrane Controlled Trials Register (CENTRAL

Full access

CLO22-053: Risk Factors of Paclitaxel Induced Peripheral Neuropathy in Early Breast Cancer Patient in Relation to Mean Changes of Neuropathy Growth Factors and Serum Malondialdehyde

Rasha Abo El Hassan, Noura Anwar Abdel-Fatah, Hadeer Khalefa Ahmed, May Shawki, and Lamia El Wkeel

risk factors for Paclitaxel induced peripheral neuropathy (PIPN). Methods : NCT03492047 is prospective randomized controlled open label study was conducted on 75 breast cancer patients receiving adjuvant paclitaxel 80 mg/m2 weekly for 12 weeks

Full access

A New Surveillance Algorithm After Resection of Colorectal Liver Metastases Based on Changes in Recurrence Risk and RAS Mutation Status

Yoshikuni Kawaguchi, Scott Kopetz, Heather A. Lillemoe, Hyunsoo Hwang, Xuemei Wang, Ching-Wei D. Tzeng, Yun Shin Chun, Thomas A. Aloia, and Jean-Nicolas Vauthey

-intent resection of CLM, it is critical to explore this issue further and develop a potential surveillance algorithm specific to this patient cohort. Within this context, the primary aim of this study was to assess the changes in recurrence risks and risk factors

Full access

Complications of Multiple Myeloma Therapy, Part 2: Risk Reduction and Management of Venous Thromboembolism, Osteonecrosis of the Jaw, Renal Complications, and Anemia

Ruben Niesvizky and Ashraf Z. Badros

preventing, identifying, and managing them. Venous Thromboembolism VTE typically manifests as deep vein thrombosis (DVT) or pulmonary embolism (PE). Both cancer and cancer treatments have been identified as discrete risk factors. 1 Current evidence

Full access

Association Between Pretreatment Skeletal Muscle and Outcomes After CAR T-Cell Therapy

Kyuwan Lee, Aleksi Iukuridze, Tianhui He, Alysia Bosworth, Lanie Lindenfeld, Jennifer Berano Teh, Meagan Echevarria, Sophia Albanese, Liezl Atencio, Rusha Bhandari, F. Lennie Wong, Andrew S. Artz, Tanya Siddiqi, Liana Nikolaenko, Jasmine Zain, Matthew Mei, Geoffrey Shouse, Leslie L. Popplewell, Alex F. Herrera, L. Elizabeth Budde, Stephen J. Forman, and Saro H. Armenian

chi-square test for categorical or 2-sided Student t tests for continuous variables. Univariable Cox proportional hazards regression was used to characterize the association between patient, disease, and CAR T-cell–related risk factors and 1-year PFS

Full access

Why, When, and How to Prevent Hepatitis B Virus Reactivation in Cancer Patients Undergoing Chemotherapy

Bhumsuk Keam, Jeong-Hoon Lee, Seock-Ah Im, and Jung-Hwan Yoon

, 30 Patients with cirrhosis are more likely to develop hepatic decompensation, resulting in hepatic failure. 5 Risk Factors for HBV Reactivation: Patient Factors, Cancer Type, and Treatment Factors Identifying risk factors for HBV reactivation

Full access

Clinicopathologic Features, Treatment Response, and Outcomes of Immune Checkpoint Inhibitor–Related Esophagitis

Kavea Panneerselvam, Rajan N. Amin, Dongguang Wei, Dongfeng Tan, Phillip J. Lum, Hao Chi Zhang, David M. Richards, Mehmet Altan, Petros Grivas, John A. Thompson, Anusha S. Thomas, and Yinghong Wang

study period (median follow-up, 15 months [IQR, 4 months to 4.2 years]); all were attributed to the patients’ malignancies. Patient Characteristics According to Esophagitis Risk Factors We compared the clinical characteristics of patients with risk

Full access

Long-Term Outcomes of Myeloid Growth Factor Treatment

Gary H. Lyman and David C. Dale

of AML/MDS increased significantly with the cumulative dose of epirubicin. In multivariate regression analysis, the cumulative doses of epirubicin and cyclophosphamide, but not of G-CSF, were independent risk factors for AML/MDS. Because G-CSF enables

Full access

NCCN Task Force Report: Breast Cancer in the Older Woman

Robert W. Carlson, Susan Moench, Arti Hurria, Lodovico Balducci, Harold J. Burstein, Lori J. Goldstein, William J. Gradishar, Kevin S. Hughes, Mohammad Jahanzeb, Stuart M. Lichtman, Lawrence B. Marks, Joan S. McClure, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Mary Lou Smith, Neal S. Topham, Tiffany A. Traina, John H. Ward, and Eric P. Winer

point system for 4-year mortality risk: 0 to 5 points: 4% or less; 6 to 9 points is 15%; 10 to 13 points is 42%; and 14 or more points is 64%. Table 4. Independent Risk Factors for 4-Year Mortality The Adjuvant! Online program provides estimates of the